SEC Filing Summary: Vital Therapies, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Vital Therapies, Inc. on May 13, 2016. The report discloses corporate governance actions regarding executive compensation approved by the Board of Directors following a recommendation from the compensation committee.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Board approved the following compensation changes effective April 1, 2016:
- Duane D. Nash, M.D.: Annual base salary set at $377,400 with a 2016 bonus target of 40% of base salary.
- Michael V. Swanson: Annual base salary set at $372,300.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, risk factors, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the effective date of the salary adjustments (April 1, 2016) against payroll records.
- Confirm the total potential compensation for Dr. Nash including the 40% bonus target.
- Note that the registrant name in the filing header is Vital Therapies, Inc., despite the request metadata referencing "IMMUNIC, INC."